New drug cocktail targets Hard-to-Treat brain cancer
NCT ID NCT05253118
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs, tislelizumab and pemetrexed, in 28 adults with a rare type of brain lymphoma (primary DLBCL of the CNS) that has relapsed or not responded to standard treatment. The goal is to see if the combination can shrink tumors and improve survival. The study is active but no longer recruiting participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab and pemetrexed
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with brain lymphoma that has returned or not responded to prior therapy.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The drugs may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Real-World data may reveal how well tafasitamab fights Hard-to-Treat lymphoma
- Off-the-Shelf immune cells take on tough lymphoma
- New cocktail aims to tame aggressive lymphoma in the very elderly
- New hope for aggressive lymphoma: triple-drug combo enters human trials
- New drug cocktail aims to tackle tough lymphoma